Network pharmacology evaluation is a powerful computational strategy for deciphering the multi-component, multi-target, and multi-pathway mechanisms of Traditional Chinese Medicine (TCM). By integrating active compound screening, target prediction, network topology analysis, functional enrichment, and molecular docking, this approach systematically reveals how herbal medicines exert therapeutic effects at the systems level. Our professional evaluation services deliver publication-ready results that accelerate mechanistic research, formula rationalization, and TCM modernization.
Technical Overview
Network pharmacology is a systems-level research paradigm first articulated in 2007 that shifts drug research away from the conventional "one disease, one gene, one target" model toward an integrated understanding of how bioactive molecules interact with biological networks. The approach is particularly well suited to Traditional Chinese Medicine, in which multi-herb formulas deliver dozens or even hundreds of compounds that act simultaneously on multiple molecular targets and signaling pathways. By constructing and analyzing compound-target-pathway-disease networks, researchers can systematically infer the pharmacological basis of herbal medicines, identify key active ingredients and hub targets, and generate testable hypotheses for downstream experimental validation.
A rigorous evaluation follows standardized methodological guidance, including the internationally recognized Network Pharmacology Evaluation Method Guidance released in 2021, which establishes best practices for database selection, screening thresholds, statistical correction, and reporting transparency. A complete workflow combines curated database mining, network topology analysis, gene functional enrichment, molecular docking, and, where required, molecular dynamics simulation and wet-laboratory verification, producing evidence that meets the requirements of peer-reviewed journals and regulatory science.
Testing Samples
Single Herbs and Crude Drug Materials
Computational evaluation can be performed on any single medicinal herb documented in public pharmacological databases, covering roots, rhizomes, leaves, flowers, fruits, seeds, and barks. Representative examples include Panax ginseng, Astragalus membranaceus, Salvia miltiorrhiza, Glycyrrhiza uralensis, Angelica sinensis, and Scutellaria baicalensis. For each herb, the full documented chemical composition is retrieved and filtered to define the biologically relevant ingredient set.
Multi-Herb Formulas and Classical Prescriptions
Complex prescriptions containing multiple constituent herbs are analyzed as integrated systems. The evaluation maps the chemical space of every herb, identifies shared and complementary targets, and quantifies the degree of synergy among components, providing a scientific rationale for classical formula composition and clinical modification strategies.
Herb Pairs and Combination Extracts
Frequently used herb pairs and two-component combinations are evaluated to characterize enhancer relationships, clarify compatibility mechanisms, and detect potential antagonistic target interactions that may inform safety assessments.
Single Compounds and Custom Compound Sets
Individual natural products, derivatives, or user-defined compound libraries can be submitted for analysis. For constituents absent from public databases, chemical structures supplied in MOL2 or SDF format are processed through ligand-based and pharmacophore-based reverse target prediction platforms.
Characterized Extracts and Fractions
When LC-MS or HPLC characterization data are available, identified constituents of an extract or fraction are directly incorporated into the analysis pipeline, enabling network pharmacology studies anchored to experimentally confirmed chemical profiles.
Testing Items
The standard evaluation portfolio covers the full analytical chain from ingredient screening to mechanistic interpretation. Core testing items include:
- Active compound screening based on oral bioavailability, drug-likeness, Caco-2 permeability, half-life, and topological polar surface area criteria.
- Compound-related target prediction and gene name standardization.
- Disease-associated target acquisition from multiple curated databases.
- Intersection target identification through Venn diagram analysis.
- Protein-protein interaction network construction and hub target screening.
- Herb-compound-target and compound-target-pathway network construction and visualization.
- Gene Ontology enrichment analysis covering biological process, cellular component, and molecular function domains.
- KEGG pathway enrichment analysis for signaling and metabolic pathway interpretation.
- Molecular docking verification of hub targets and key active compounds.
- Molecular dynamics simulation and binding free energy calculation as advanced options.
- Optional toxicity prediction, therapeutic area annotation, and drug-likeness re-evaluation of candidate compounds.
Testing Methods
Active Compound Screening and Target Prediction
Chemical constituents and their pharmacokinetic parameters are retrieved from authoritative sources including TCMSP, TCMID, BATMAN-TCM, SymMap, and the HERB database. Constituents meeting the widely accepted thresholds of oral bioactivity greater than or equal to 30 percent and drug-likeness greater than or equal to 0.18 are retained as candidate active compounds. Corresponding protein targets are collected, deduplicated, and mapped to standardized human gene symbols using the UniProt database.
Disease Target Collection and Integration
Disease-related targets are systematically mined from GeneCards, OMIM, DisGeNET, PharmGkb, and DrugBank using defined search terms, with relevance scores applied where applicable. Redundant entries are removed after cross-database integration, and the intersection between compound targets and disease targets is extracted as the therapeutic target set.
Network Construction and Topological Analysis
Protein-protein interaction data are obtained from the STRING database with the combined confidence score set to medium or high stringency and the species restricted to Homo sapiens. Networks are visualized and analyzed in Cytoscape, and topological parameters including degree, betweenness centrality, and closeness centrality are calculated using plugins such as CytoNCA and CentiScaPe. Nodes exceeding the median or twice-median thresholds are defined as hub targets, and module-level analysis may be performed using the MCODE plugin.
Functional Enrichment Analysis
Gene Ontology and KEGG pathway enrichment analyses are conducted using DAVID, Metascape, or the R clusterProfiler package. Results are filtered using a corrected false discovery rate or adjusted p-value below 0.05 with Benjamini-Hochberg correction, and the top terms are presented as bubble plots, bar charts, and circos diagrams.
Molecular Docking and Simulation
Three-dimensional structures of hub targets are obtained from the PDB database, prepared through dehydration, hydrogenation, and active pocket definition, while ligand structures are energy-minimized before docking. Docking is performed with AutoDock Vina, CB-Dock, or Discovery Studio, and binding energies below -5.0 kcal/mol are interpreted as favorable binding affinity, with values below -7.0 kcal/mol indicating strong interactions. Docking poses are rendered in PyMOL, and molecular dynamics simulations of selected complexes can be extended to 100 nanoseconds or longer to assess binding stability.
Applications
Network pharmacology evaluation supports a broad spectrum of academic and translational objectives in natural product and integrative medicine research:
- Mechanistic elucidation of single herbs, herb pairs, and classical formulas in specific diseases such as tumors, metabolic disorders, cardiovascular disease, neurodegeneration, and inflammatory conditions.
- Scientific interpretation of TCM compatibility principles, including monarch-minister-assistant-envoy logic and synergy between paired herbs.
- Identification of quality markers and bioactive indicator components for herbal quality control standardization.
- Drug repurposing and lead compound discovery by mining hub targets shared across diseases.
- Biomarker discovery and patient stratification hypotheses for precision medicine studies.
- Adjuvant therapy research, including mechanistic analysis of herbal compounds combined with chemotherapy, immunotherapy, or targeted agents.
- Publication support for SCI-indexed journals, dissertation chapters, and grant applications requiring standardized computational evidence.
FAQ
What information is required to initiate an evaluation?
Researchers need to provide the names of the herb or formula constituents, the disease or clinical indication of interest, and any known chemical characterization data. Optional inputs include predefined screening thresholds, target databases of preference, and candidate hub targets for focused docking studies.
How long does a complete analysis take?
A standard single-formula, single-disease evaluation is typically completed within two to four weeks, including enrichment analysis and molecular docking. Projects involving molecular dynamics simulation, multi-disease comparison, or large custom compound sets may require four to eight weeks depending on computational scale.
What deliverables are provided?
Deliverables include all raw data files, screening tables, Venn diagrams, network maps, protein-protein interaction figures, GO and KEGG enrichment plots, docking pose images with binding energy tables, and a written methods section formatted for manuscript submission.
Can compounds that are not present in public databases be analyzed?
Yes. Structures submitted in MOL2 or SDF format are processed through SwissTargetPrediction and PharmMapper for reverse target fishing, after which the compounds enter the standard network and enrichment pipeline on equal footing with database-derived ingredients.
Is experimental validation support available?
Computational results can be packaged into a validation plan recommending qPCR, Western blot, ELISA, cellular assay, or animal model experiments for the predicted hub targets and pathways, and projects can be extended through coordination with partner laboratories for wet-lab confirmation.
How is analytical quality assured?
All analyses follow the 2021 Network Pharmacology Evaluation Method Guidance, employ at least two independent databases for target retrieval, apply statistically corrected enrichment thresholds, and document every parameter in the final methods section to ensure reproducibility and journal compliance.
